4.6 Article

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation

Journal

MOLECULES
Volume 27, Issue 23, Pages -

Publisher

MDPI
DOI: 10.3390/molecules27238264

Keywords

shikonin; leukemia; Wilms' tumor gene 1 (WT1); CD34; cell differentiation

Funding

  1. National Natural Science Foundation of China for Young Scholar
  2. Youth Natural Science Foundation of Henan Province
  3. China Postdoctoral Science Foundation
  4. Postgraduate Education Innovation and Quality Improvement Project of Henan University
  5. [82104697]
  6. [212300410109]
  7. [2021M690912]
  8. [SYL19060139-140]
  9. [SYL20060159-160]

Ask authors/readers for more resources

This study aimed to observe the differentiation effect of shikonin on Wilms' tumor 1 (WT1)-positive HL-60 cells and investigate the fate of the differentiated leukemia cells. The results showed that shikonin could decrease the WT1 protein level, promote leukemia cell differentiation, and inhibit cell proliferation while inducing apoptosis. The study also provided preliminary evidence for the protein-protein interactions between WT1 and CD34, suggesting their potential involvement in cell immaturity.
This study aims to observe the differentiating effect of shikonin on Wilms' tumor 1 (WT1)-positive HL-60 cells and investigate the fate of the differentiated leukemia cells. WT1 overexpression unaffected cell viability but promoted resistance to H2O2-induced DNA injury and cell apoptosis. The binding of shikonin to the WT1 protein was confirmed by molecular docking and drug affinity reaction target stability (DARTS). Shikonin at the non-cytotoxic concentration could decrease the WT1 protein and simultaneously reduced the CD34 protein and increased the CD11b protein in a dose-dependent manner in normal HL-60 cells but not in WT1-overexpressed HL-60 cells. Shikonin unaffected HL-60 cell viability in 48 h. However, it lasted for 10 days; could attenuate cell proliferation, mitochondrial membrane potential (MMP), and self-renewal; prevent the cell cycle; promote cell apoptosis. In a mouse leukemia model, shikonin could decrease the WT1 protein to prevent leukemia development in a dose-dependent manner. In this study, we also confirmed preliminarily the protein-protein interactions between WT1 and CD34 in molecular docking and CO-IP assay. Our results suggest that: 1. shikonin can down-regulate the WT1 protein level for leukemia differentiation therapy, and 2. the interaction between WT1 and CD34 proteins may be responsible for granulocyte/monocyte immaturity in HL-60 cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available